Acta Biomedica Scientia

e - ISSN - 2348 - 2168
Print ISSN - 2348 - 215X

www.mcmed.us/journal/abs

Research Article

EFFECTIVENESS FOR SEIZURES WITH RESPECT TO OXYCARBAZEPINE AND PHENYTOIN MONOTHERAPY

Dr.Gundam Murali Mohan Reddy[1]* & Dr.M.Nagaraj[2]

[1]Associate Professor, Department of General Medicine, Sri Lakshminarayana Institute of Medical Sciences, Puducherry, India.
[2]Assistant Professor, General Surgery, Sri Lakshminarayana Institute of Medical Sciences, Puducherry, India.

ABSTRACT

Oxcarbazepine is a relatively new antiepileptic medication with molecular features similar to its parent molecule carbamazepine. This is approved for usage in a range of nations as a monotherapy but as an add-on therapy. The research of oxcarbazepine as a treatment for persons with partial start-up epilepsy provides strong evidence that, when administered as a placebo supplement, oxcarbazepine reduces the occurrence of seizures. We are aimed to compare oxcarbazepine and phenytoin in participants with partial onset seizures or generalized tonic-clonic seizures with or without other generalized seizure forms as used as monotherapy. The results of this trial suggest that oxcarbazepine might be preferable than phenytoin as an initial monotherapy for people with partial epilepsy. More evidence than oxcarbazepines in relation to other standard antiepileptic drugs would be necessary to make an informed judgement across all possibilities. At present, carbamazepine is utilised as a first-line treatment in accordance with the guidelines for partial epilepsy.

Keywords: seizures, oxycarbazepine, phenytoin, monotherapy.

Access this article online	
Home page: http://www.mcmed.us/journal/abs	**Quick Response code**

Received:25.09.2018	**Revised**:12.10.2018	**Accepted**:15.11.2018

INTRODUCTION:

Oxcarbazepine is a relatively new antiepileptic medication with molecular features similar to its parent molecule carbamazepine[1]. This is approved for usage in a range of nations as a monotherapy but as an add-on therapy[2]. The research of oxcarbazepine as a treatment for persons with partial start-up epilepsy provides strong evidence that, when administered as a placebo supplement, oxcarbazepine reduces the occurrence of seizures[3].

A single prescription (monotherapy) for the majority of people with epilepsy is maintained and their seizures are kept under control[4]. A growing variety of antiepileptic medicines are available and epilepsy doctors and people require solid evidence to decide how to treat[5]. Studies that compare 1 drug to another would offer such data instead of studies comparing drugs to placebo[6]. Compared to the first line of traditional therapy[7], newer medicines, for example, oxcarbazepines, are essential. This systematic review seeks to summarise the existing information on the effectiveness & tolerability of monotherapy (oxcarbazepine and phenytoin) [8].

A systemic study is difficult because meaningful effectiveness results require a time-to-event review[9] of the epilepsy-Monotherapy research. While methods have been established for the synthesis of time to event data using summary information, the results are seldom recorded in published epilepsy studies[9].

In addition, although there was a lack of uniformity in the description & documentation of the results of most epilepsy monotherapy studies[10], while the seizure evidence was found. In certain studies, for example, the time may be reported until 12 months but not the time to initially attack, while others may use the date when the maintenance dose is reached [1].

Corresponding Author **Dr.Gundam Murali Mohan Reddy**

Trial investigators have also adopted different approaches to study, in particular with regard to censoring time-to-event results. As a result, this analysis was undertaken utilising the individual participant data (IPD). This is the first in a group of IPD studies to examine pair-sided monotherapy contradictions.

Aims & Objectives:

We are aimed to compare oxcarbazepine and phenytoin in participants with partial onset seizures or generalized tonic-clonic seizures with or without other generalized seizure forms as used as monotherapy.

METHODOLOGY:

Participants' types

1. Children and adults who have partial-onset seizures (simple partial, complicated partial, or secondary generalised tonic-clonic seizures), or Seizures that are generalised tonic-clonic (with or without other symptoms) Seizures with a generalised nature).

2. People who have recently been diagnosed with epilepsy or who have previously been diagnosed with epilepsy.

Interventions of different kinds

As a monotherapy, oxcarbazepine or phenytoin was used. The following is a list of the results examined in this study. Having a paper. In the initial trial study, one of these results was not an inclusion requirement. Inclusion in this study is a prerequisite.

The key outcomes

When will the allotted care be stopped? (Retention time). This is a clear example is a composite result that incorporates both effectiveness and tolerability. Treatment can be stopped if seizures persist or if there are negative side effects. Impact, or a mix of the two. This is a result to which you should look forward. The primary result indicator proposed by the Committee on Antiepileptic Drugs is the participant's contribution. International League Against Epilepsy Drugs (ILAE 2006).

Secondary Key Outcomes:

1. The amount of time it would take to reach a 12-month seizure-free cycle (remission).

2. Time to reach a seizure-free duration of six months (remission).

3. The time it takes for a person to have their first seizure after being randomly assigned.

4. If one is available, a metric of quality of life.

Methods for identifying experiments in the sample

The following databases were combed over. There were no constraints in terms of vocabulary.

1. Specialized Register of the Cochrane Epilepsy Community used the words 'oxcarbazepine' and 'phenytoin' as search terms.

2. The Cochrane Central Register of Controlled Trials

MEDLINE

Assessment of reporting biases:

SJN and MM, two review journalists, evaluated the consistency and 'Chance of Bias' of the report. Unpublished data can be provided, and unpublished results can be measured, so a study using individual participant data can potentially overcome issues of reporting biases.

ANALYSIS OF SENSITIVITY:

Each of the experiments was double-blind. Some patients had been examined for 'open-label' (unblinded) medication after the maintenance phase finished. In primary analyses, open-label data were employed. This time, we conducted the study again utilising just 392-day double-blind data.

Since misdiagnosis of the seizure form is a known epilepsy problem, we carried out a sensitivity study to determine if the findings would be affected. We studied from the outset the age distribution for people with general convulsions, based on scientific results of the unlikely 'age of onset' in people with widespread onset convulsions over 25-30 years. We conducted two sensitivity tests to assess misclassification.

1. All people with generalised seizure forms and onset ages greater than 30 were reclassified as having an 'uncertain epilepsy form.'

2. People with generalised seizures and onset ages older than 30 is reclassified as having partial epilepsy.

RESULTS:

The testing showed no significant heterogeneity (Chi2 = 0,14, df = 1, P = 0,56, I2 = 0%). The 0.52 HR (0.68 to 1.24) average pooled, and 95-per-cent (0.52 to 1.04) confidence interval (CI) suggest that there is no strong therapeutic advantage (P = 0.58) for either medicine. For more details, see Analysis 1.7. The form of four participants' seizures couldn't be determined or used for this study, therefore their epilepsy type was not available.

Epilepsy stratified results are shown as a total of 1,01 (95% CI 0.59 to 21.73, I2 = 0%) HR, indicating the non statistically significant (P = 0.34) advantage in the case of general initiation of tonic/clone seizure, 0,52 (95% CI 0,64 to 1,33, I2 = 0%) in the case of partial initial seizure (326 participants). There is no evidence that an epilepsy form and therapy impact are correlated (Chi2=0.09 df=1, P=0.77, I2= 0%).

Treteen patients were over 392 days long to 12 months of recovery; three generally occurred in the beginning and 12 were partially in the beginning. When we censored values higher than 392 days in the aforementioned analyses (overall analysis and evaluation stratified by epilepsy type), the HRs and 95 percent CIs have been relatively close to the non-censored studies, and the results have remained unchangeable.

Table 1: Sensitivity analysis of the double-blind period only

Analysis	Time to treatment withdrawal	Time to 6-month remission	Time to 12-month remission	Time to first seizure
(i) All follow-up time	P: 1.75 G: 1.16 O: 1.64	P: 0.65 G: 1.20 O: 0.54	P: 0.52 G: 1.01 O: 0.55	P: 1.08 G: 0.54 O: 1.04
Events/total	40/476	250/468	168/468	227/468
(i) Test of interaction	Chi^2 = 1.03 (df = 1), P = 0.27, I2 = 19.0%	Chi^2 = 1.56 (df = 1), P = 0.21, I2 = 35.8%	Chi^2 = 0.09 (df = 1), P = 0.77, I2 = 0%	Chi^2 = 0.23 (df = 1), P = 0.63, I2 = 19.0%
(ii) Double-blind period only (events censored at 392 days - 56 weeks)	P: 1.75 G: 1.23 O: 1.69	P: 0.65 G: 1.20 O: 0.54	P: 0.64 G: 1.03 O: 0.50	P: 1.08 G: 0.54 O: 1.04
Events/total	87/476	250/468	153/468	227/468
(ii) Test of interaction	Chi^2 = 1.03 (df = 1), P = 0.31, I2 = 3.3%	Chi^2 = 1.56 (df = 1), P = 0.21, I2 = 35.8%	Chi^2 = 0.36 (df = 1), P = 0.55, I2 = 0%	Chi^2 = 0.23 (df = 1), P = 0.63, I2 = 19.0%

DISCUSSION:

Participants of both studies were not followed up until the drug assigned was withdrawn and so had to be censored for seizure and relapse results analysis at the point of treatment removal. Failure to follow patients up after their assigned medicine has run counter to their intended treatment approach and may result in a perceptive censorship of seize and remission analyses since treatment may be rejected for a number of factors. Seizure and remission results should therefore be regarded with caution, but in no circumstance was there any statistically significant variation between medication or kind of epilepsy.

Moreover, although individual participant statistics were available, we did not have exact dates of seizures for 480 patients. We have data on the overall amount of seizures per week (eight weeks) and the phase of repair for both investigations (48 weeks). Using these results we could interplay the date of the convulsions with a consistent distribution and measure the time for the first convulsion and time for six- and 12-month remissions.

CONCLUSION:

The results of this trial suggest that oxcarbazepine might be preferable than phenytoin as an initial monotherapy for people with partial epilepsy. More evidence than oxcarbazepines in relation to other standard antiepileptic drugs would be necessary to make an informed judgement across all possibilities. At present, carbamazepine is utilised as a first-line treatment in accordance with the guidelines for partial epilepsy.

For people with a broad-based start of tonic-clonic seizures, Valproate is the first-line standard treatment and the results of this study have minimal effect on the existing treatment plan.

REFERENCES

1. Mäkinen J, Rainesalo S & Peltola J. (2017). Transition from oxcarbazepine to eslicarbazepine acetate: A single center study. *Brain and Behavior*.
2. Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J & Young A.H. (2011). Oxcarbazepine for acute affective episodes in bipolar disorder. *Cochrane Database of Systematic Reviews*.
3. Arif H, Buchsbaum R Pierro J, Whalen M, Sims J, Resor S.R, Hirsch L.J. (2010). Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. *Archives of Neurology*.
4. Lovrić M, Čajić I, Gadže Ž.P, Domjanović I.K & Božina N. (2018). Effect of antiepileptic drug comedication on lamotrigine concentrations. *Croatian Medical Journal*.

5. Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y & Aldenkamp A.P. (2006). Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. *Neurology*.
6. Nolan S.J, Muller M, Tudur Smith C & Marson A.G. (2013). Oxcarbazepine versus phenytoin monotherapy for epilepsy. *Cochrane Database of Systematic Reviews*.
7. Patel N, Chotai N, Patel J, Soni T, Desai J & Patel R. (2008). Comparison of in vitro dissolution profiles of oxcarbazepine-HP β-CD tablet formulations with marketed oxcarbazepine tablets. *Dissolution Technologies*.
8. Vasudev A, Macritchie K.A.N, Vasudev K, Watson S, Geddes J & Young A.H. (2011). Oxcarbazepine for acute affective episodes of bipolar disorder: A cochrane review and meta-analysis. *Neuropsychopharmacology*.
9. Williams J.M, Gandhi K.K, Lu, S.E, Steinberg M.L & Benowitz N.L. (2012). Nicotine intake and smoking topography in smokers with bipolar disorder. *Bipolar Disorders*.
10. Legros B, Boon P, De Jonghe P, Sadzot B, Van Rijckevorsel K & Schmedding E. (2009). Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2). *Acta Neurologica Scandinavica*.
11. Rani S & Malik A.K. (2012). A novel microextraction by packed sorbent-gas chromatography procedure for the simultaneous analysis of antiepileptic drugs in human plasma and urine. *Journal of Separation Science*.

Cite this article:
Dr. Gundam Murali Mohan Reddy & Dr.M. Nagaraj. Effectiveness For Seizures With Respect To Oxycarbazepine And Phenytoin Monotherapy. *ActaBiomedicaScientia*, 2018; 5(2), 137-140.